Breast cancer (BC) is a very heterogeneous disease [8] which is traditionally classified in three major groups for clinical purposes, i.e., estrogen-receptor-positive (ER+), HER2-positive (HER2+) and triple-negative (TNBC). This evidence concerns the gene ERBB2 and breast carcinoma.